phone: +48 22 721 40 00   /  fax: +48 22 721 13 33  /   bioinfo@bioton.pl



Management of the Company



PROFESSIONAL CURRICULA VITAE OF MEMBERS OF THE MANAGEMENT BOARD AND THE SUPERVISORY BOARD OF BIOTON S.A.

 

Management Board

 

Robert Neymann – President of the Management Board

In the years 1982–1987, Mr. Robert Neymann studied at the Warsaw School of Economics (major: Finance).

 

Mr. Robert Neymann’s work experience:

  • 1987 to 1990, at OMC Poll Ltd. as a financial comptroller at the Controlling Department; Sales Manager for the Blendax product line in Poland;
  • 1990 to 1991, at Procter & Gamble Polska as National Key Account Manager;
  • 1991 to 1993, at Procter & Gamble Polska as Unit Sales Manager (Northern Poland);
  • 1993 to 1994, at Procter & Gamble Polska as Trade Marketing Manager;
  • 1994 to 1996, at Procter & Gamble Polska as District Sales Manager (Central and Northern Poland);
  • 1996 to 1999, at Procter & Gamble Central and Eastern Europe as Distributor Operations Manager Cⅇ
  • 1999 to 2000, at Procter & Gamble Western Europe as Laundry Additives Customer Business Development Manager Western Europe;
  • 2001 to 2005, at Herbapol Lublin S.A. as Vice President of the Management Board for Commercial Affairs;
  • 2005 to 2007, at Polsnack Sp. z o.o. as President of the Management Board;
  • 2009 to 2011, at Harper Trade Sp. z o.o. as President of the Management Board;
  • 2007 to 2017, at Harper Hygienics S.A. as President of the Management Board. 

 

Marek Dziki - Member of the Management Board

Education:

2004 – 2005 - Merck University (Kellog Business School, Chicago, Hong Kong University of Science and Technology, Business School in Fountainebleu),

1996 – 1998 - Master of Business Administration at the International Business School in Warsaw, Poland,

1988 – 1990 - Ph.D., Medical University in Lublin, Poland,

1982 – 1988 - Medical Doctor Degree, The Medical University in Lublin, Poland.

 

Professional experience:

  • M&M Pharma, Warsaw, Poland | President (March 2014 – present),
  • Lumeden (Zurich, Odessa and Moscow) | CEO (August 2013 – December 2014), Consultant (January 2015 – present),
  • Skolkovo Innovation Centre, Moscow, Russia | Executive Director of the Biomed Cluster (January 2012 – December 2013),
  • Merck Limited, Mumbai, India | Managing Director (August 2006 – September 2012),
  • Merck Darmstadt | Vice President and Head of Strategic Innovation (October 2005 – July 2006),
  • Merck Austria | General Manager (January 2001 – September 2005),
  • Merck Poland | Head of the Pharmaceutical Division (May 1998 – December 2000),
  • Merck Poland | Head of Business Development (October 1997 – April 1998),
  • Merck Poland | Sales and Marketing Manager (January 1994 – September 1997),
  • Merck Poland | Medical Representative in Lublin (September 1992 – December 1993),
  • Medical University of Lublin | Associate Professor (1991 – 1992),
  • Medical University of Hanover, Germany | Research Grant (1991),
  • Medical University of Lublin | Assistant Lecturer (1998 – 1990).

 

 

Adam Polonek – Member of the Management Board

Is a graduate of the University of Economics in Katowice. He has extensive knowledge and experience in managing finances of companies and capital market. Since 2006 he has been an employee of BIOTON S.A. where he was holding first the position of deputy Chief Financial Officer and then the position of Chief Financial Officer. During this time he had the opportunity to improve his knowledge and competence in managing finances of the company, debt funding, development projects and restructuring transactions. Is also performing shareholding supervision in the subsidiaries of BIOTON S.A. In 2000-2006 was employed at CAIB Financial Advisers (at present UniCredit CAIB Poland), holding the positions from an analyst to a deputy director, where he was dealing with consultancy in mergers and acquisitions, evaluation of enterprises and optimization of financing structures. He has participated in a number of training within the scope of international accounting standards, evaluation of enterprises and project management. He is fluent in English. Since 20 December 2011 he has been holding the function of a Member of the Management Board of BIOTON S.A.

 

Supervisory Board

 

Jubo Liu – Chairman of the Supervisory Board

Mr. Jubo Liu is the founder and has served as the CEO of Cogenes Biotechnology Incorporation (focused on in vitro diagnosis R&D, manufacturing and marketing) since August 2011 and is the founder and has served as the CEO of NovoTek Pharmaceuticals Limited (Hong Kong) and Beijing NovoTek Medicinal Technology Development Co. Ltd (Beijing) (international platform to globalise healthcare products both from within and outside of China) since August 2009. From April 2008 to July 2009 he was the China Chief Representative of Immtech Pharmaceuticals Inc. (US New York) (establishing Chinese activity infrastructure and investment plans). From November 2007 to April 2008, he acted as a Clinical Trial Liaison with US-based Pharmaceuticals Inc. (US New York) (carrying out global clinical trial operation in China). From October 2006 to November 2007 he was a scientist at Boston Vertex Pharmaceuticals Inc. (formulation and drug delivery). From July of 2005 to January of 2007 he was as a cofounder and served as the Director of Business Development of JCS Biopolytech Incorporation (modified biopolymer R&D and marketing used for drug delivery and nanotechnology). From August 1997 to February 2001, he served as the Director of Marketing and Regulatory Affairs for Huayuanlong Medicinal Technology Development Co. Ltd. of Beijing, China. Mr. Liu obtained his Bachelor’s Degree in Pharmacy from the Department of Pharmacy of the Pharmaceutical University of Shenyang (September 1992 to July 1997) and a Ph.D. from the Department of Pharmaceutical Sciences at the University of Toronto (from September 2002 to October 2006). Furthermore, Mr. Liu is an author or co-author of several publications regarding medical and biological issues.

 

Dariusz Trzeciak – Vice Chairman of the Supervisory Board

He has completed 4-year PhD studies at the Law and Administration Faculty of the University of Warsaw, Postgraduate MBA Studies at the Warsaw School of Economics and Law and Administration Faculty and History Faculty of the University of Warsaw. In the past he held managerial and supervisory positions in many companies, including the function of the President of the Management Board of Towarzystwo Ubezpieczeń na Życie Polisa Życie S.A., Sferia S.A., IT Polpager S.A. At present he holds the position of: a Member of the Management Board of Sferia S.A. and Vice-Chairman of the Supervisory Board of Radio PIN S.A.

 

Ming-Tso Mark Chiang – Member of the Supervisory Board

Received PhD degree in Computer Science in University of London and had more than five years of working experience as an analyst. Solid commercial excellence experience in MNC pharmaceutical since the end of 2009. This covers numerous sales and marketing initiatives including segmentation and targeting process, territory alignment, incentive scheme design, CRM system design, multichannel marketing roadmap design, reporting dashboards and training and coaching. Strong experience on business operation and cross functional collaboration.

 

Vaidyanathan Viswanath – Member of the Supervisory Board

Is a post-graduate in Pharmacology with about 3 decades experience in sales, marketing, business development and strategic planning in the pharmaceutical industry across Asia. His previous experience includes Serum Institute (Serono) and Astra in India both in sales and marketing, 8 years with Pharmacia in India and China. He was then the BD and Strategic Planning Director for Pfizer China and BD Director - Asia for Capsugel (Division of Pfizer) until 2011 based in Bangkok. Currently living in Beijing, Vaidyanathan Viswanath is an Independent Consultant for a number of pharma companies and in this role offers his expertise in the area of Strategic Marketing, Business Development, Marketing and Sales Effectiveness, Alliance Management, KOL & Advocacy development. With his deep understanding of the trends in the industry backed up by his strong networking capabilities, Vaidyanathan Viswanath envisions to act as a bridge for these companies to reach out to companies overseas and visa versa.

 

Paweł Borowy – Member of the Supervisory Board

Is a graduate of Banking and Finance faculty in Szkoła Główna Handlowa in Warsaw. In 2010 he completed a 2 year management training program wchich was created in cooperation with Insead Business School and TiasNimbas Business School. Member of ACCA (the Association of Chartered Certified Accountants) since 2003.

From 1999 CFO of the company: TempService Sp. z o.o., acquired in 2004 by Randstad Holding NV – a leading global staffing and recruitment company. He was responsible for co-creating and implementation of the financial strategies. He participated in several merger and restructuring processes in Poland. He was responsible for improvement of operational effectiveness, implementation of new services, change management of reporting and forecasting of business results. He took active part in the implementation of SAP, an ERP system. From 2013 CFO Central Eastern Europe, responsible for creating of reporting structures of CEE region, and supervision of Randstad operations in five countries (Czech, Slovakia, Hungary, Greece, Turkey).

Since 2016 till today, CFO of Mobilis Sp. z o.o., one of the leaders in bus transportation services, responsible for all financial aspects of the operations in Poland.


Mr. Qi Bo – Member of the Supervisory Board

Professional Experience

Mr. Qi Bo has over twenty-five years of proven track record of achievement in major leading biopharmaceutical companies in US and China, with solid knowledge and experience in pharmaceutical drug lifecycle including process development, validation, technology transfer, manufacturing and regulatory filing. He worked on multiple world-wide approved recombinant protein/monoclonal antibody products, e.g. Aranesp (Amgen), Erbitux (ImClone) and Cyramza (Lilly) and Portrazza (Lilly).

  • Genron corporation, CHINA/Vice President and Head of CMC, General Manager of Generon Beijing Plant (2015-Present)
  • Eli Lilly and Company (NJ), US/ Director of CMC Development (2008-2015)
  • ImClone System Inc., NJ, US/Director of Process Development (2002-2008)
  • Amgen Inc., CA, US /Associate Scientist of Process Development (1992-2002)

Education

  • M.Sc in Biochemistry, University of Minnesota, US (1988-1991)
  • B.Sc in Biochemistry, East China Univ. of Sci & Tech, China (1980-1984)

 

Mr. Gary He – Member of the Supervisory Board

Mr. Gary He is the Vice President of CMC Global Compliance at Generon Corporation Ltd. since Nov. 2016. From April 2004 to Oct 2016 he was an Associate Director at Eli Lilly & Company (US New Jersey) (served as a member of the Site Management Team, the Change Board, the Quality Board, and the Engineering Team to manage the site wide production and quality activities). From September 2001 to April 2004, he acted as a senior consultant at Bristol-Myers Squibb (US New Jersey). From April 1995 to August 2001 he was a senior engineer at Lockwood Greene Engineering (US New Jersey). From January of 1994 to January of 1995 he was a validation engineer at Qualis Inc. (US Iowa). From August 1984 to February 1990, he served as a project engineer/product supervisor at No. 3 Pharmaceutical Company in Shanghai. Mr. He obtained his Bachelor’s Degree in Biochemical Engineering from East China Technical Institute, Shanghai, P.R. China (from September 1980 to July 1984) and a Master’s Degree in Chemical Engineering from Wayne State University, Michigan (from September 1990 to
September 1993).

 

© 2017 BIOTON S.A.